Rafael was nominated in the Pipelines of Promise category this year
Newark, NJ, June 04, 2018 (GLOBE NEWSWIRE) -- Sanjeev Luther, President & CEO of Rafael Pharmaceuticals, Inc., will present the company’s clinical development strategy as Rafael prepares for its upcoming pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML).
Interviews with Mr. Luther are available upon request.
WHERE: Theater 1, Boston Convention & Exhibition Center: 415 Summer St, Boston, MA 02210.
WHEN: Wednesday, June 6th, 5:00 PM
CONTACT: Jacob Jonas, 973-438-3176 or email@example.com
About Rafael Pharmaceuticals, Inc.
Rafael Pharmaceuticals, Inc. is a clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael’s primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Rafael’s first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. CPI-613 has been granted orphan drug designation for the treatment of pancreatic cancer, AML, myelodysplastic syndromes (MDS), Burkitt’s lymphoma, and T-cell lymphoma. For more information, visit http://www.rafaelpharma.com/.